ReviewCurrent opinion in HIV and AIDS2012
Next-generation oral preexposure prophylaxis: beyond tenofovir.
Review in Current opinion in HIV and AIDS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 29 citations in OpenAlex.
- Exploring Perceived Barriers and Facilitators of PrEP Uptake among Young People in Uganda, Zimbabwe, and South Africa.Archives of sexual behavior · 2021Article
- Sustained-release Griffithsin nanoparticle-fiber composites against HIV-1 and HSV-2 infections.Journal of controlled release : official journal of the Controlled Release Society · 2020Article
- Community perspectives on barriers and challenges to HIV pre-exposure prophylaxis access by men who have sex with men and female sex workers access in Nigeria.BMC public health · 2020Article
- Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase.Future science OA · 2018Review
- A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective.Infectious diseases and therapy · 2017Review
- Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.CPT: pharmacometrics & systems pharmacology · 2016Article
- Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.Antimicrobial agents and chemotherapy · 2016Article
- The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention.Journal of the International AIDS Society · 2015Article
- PrEP Implementation Science: State-of-the-Art and Research Agenda.Journal of the International AIDS Society · 2015Article
- Adherence to preexposure prophylaxis: current, emerging, and anticipated bases of evidence.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- Young adult women and correlates of potential adoption of pre-exposure prophylaxis (PrEP): results of a national survey.Current HIV research · 2013Article
- Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison.Antimicrobial agents and chemotherapy · 2013Article
- Antiretroviral pharmacology in mucosal tissues.Journal of acquired immune deficiency syndromes (1999) · 2013Review
- Article
- HIV integrase inhibitors: 20-year landmark and challenges.Advances in pharmacology (San Diego, Calif.) · 2013Review
- Pre- and post-sexual exposure prophylaxis of HIV: An update.Indian journal of sexually transmitted diseases and AIDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewClinical trials of oral preexposure prophylaxis (PrEP) have focused on regimens of tenofovir (TDF) with or without emtricitabine (FTC). However, TDF may be associated with toxicities (renal, bone), and FTC may select for drug resistance. Both are also first-line drugs for HIV treatment. In this review, we discuss agents that might serve as alternatives to TDF/FTC for HIV PrEP. RECENT
findingsSeveral drug characteristics are important to consider when selecting agents for PrEP with the most critical being safety, tolerability, adequate penetration into target tissues for prevention of HIV infection, and long-lasting activity with convenient dosing. With these factors in mind, we review five potentially useful agents for PrEP. The first group includes drugs that are already Food and Drug Administration approved (maraviroc, raltegravir) with attributes that make them attractive for PrEP. The second group includes investigational agents with long-lasting activity that are being developed in parenteral form (rilpivirine-long acting, S/GSK1265744, ibalizumab). SUMMARY: Future PrEP drugs may give clinicians the flexibility to select agents on the basis of individual patient needs and preferences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.